Condition: Hepatocellular Carcinoma · Hepatic Portal Vein Tumor Invasion · Tumor Thrombus · Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab/Bevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I/II PVTT (Based on Cheng's PVTT classification).
This description comes directly from the study's public registry record.
Mingsheng Huang, M.D. & Ph.D. · +86-02085253416 · huangmsh@mail.sysu.edu.cn
Luwen Mu, M.D. · +86-13660534361 · mulw@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| The Third Affiliated Hospital of Sun Yat-Sen University | Guangzhou, Guangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05984511